Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients
Main Article Content
Keywords
melanoma, gene expression profile, clinical decision-making, disease management
Abstract
Objective: A 31-gene expression profile (GEP) test that has been clinically validated identifies melanoma patients with low (Class 1) or high (Class 2) risk of metastasis based on primary tumor biology. This study aimed to prospectively evaluate the test impact on clinical management of melanoma patients.
Methods: Physicians at 16 dermatology, surgical or medical oncology centers examined patients to assess clinical features of the primary melanoma. Recommendations for clinical follow-up and surveillance were collected. Following consent of the patient and performance of the GEP test, recommendations for management were again collected, and pre- and post-test recommendations were assessed to determine changes in management resulting from the addition of GEP testing to traditional clinicopathologic risk factors.
Results: Post-test management plans changed for 49% (122 of 247) of cases in the study when compared to pre-test plans. Thirty-six percent (66 of 181) of Class 1 cases had a management change, compared to 85% (56 of 66) of Class 2 cases. GEP class was a significant factor for change in care during the study (p<0.001), with Class 1 accounting for 91% (39 of 43) of cases with decreased management intensity, and Class 2 accounting for 72% (49 of 68) of cases with increases.
Conclusions: The reported study show that the 31-gene GEP test improves net health outcomes in the management of cutaneous melanoma. Physicians used test results to guide risk-appropriate changes that match the biological risk of the tumor, including directing more frequent and intense surveillance to high-risk, Class 2 patients.
References
1. Coit DG, Thompson JA, Albertini MR, et al. Melanoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. 2018.
2. Shaikh WR, Dusza SW, Weinstock MA, et al. Melanoma Thickness and Survival Trends in the United States, 1989 to 2009. Journal of the National Cancer Institute. 2016 Jan;108(1). doi: 10.1093/jnci/djv294. PubMed PMID: 26563354; PubMed Central PMCID: PMC4857148.
3. Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. The Journal of investigative dermatology. 2015 Apr;135(4):1190-3. doi: 10.1038/jid.2014.452. PubMed PMID: 25330295.
4. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. The New England journal of medicine. 2014 Feb 13;370(7):599-609. doi: 10.1056/NEJMoa1310460. PubMed PMID: 24521106; PubMed Central PMCID: PMC4058881.
5. Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. European journal of cancer. 2015 Mar;51(5):653-67. doi: 10.1016/j.ejca.2015.01.007. PubMed PMID: 25638778.
6. Park TS, Phan GQ, Yang JC, et al. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Annals of surgical oncology. 2017 Apr;24(4):947-951. doi: 10.1245/s10434-017-5768-8. PubMed PMID: 28144760; PubMed Central PMCID: PMC5339323.
7. Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. Journal of the American Academy of Dermatology. 2016 Sep;75(3):516-24. doi: 10.1016/j.jaad.2016.02.1229. PubMed PMID: 27183845.
8. Lyle M, Lee, JHJ, Menzies, AM, Chan, MMK, Clements, A, Carlino, MS, Kefford, R, Long, GV. Lesion-specific patterns of response and progression with anti-PD1 treatment in metastatic melanoma (MM). Journal of Clinical Oncology. 2014;32(15_suppl):9077.
9. Menzies AM, Haydu LE, Carlino MS, et al. Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PloS one. 2014;9(1):e85004. doi: 10.1371/journal.pone.0085004. PubMed PMID: 24400126; PubMed Central PMCID: PMC3882277.
10. Nishino M, Giobbie-Hurder A, Ramaiya NH, et al. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014;2(1):40. doi:10.1186/s40425-014-0040-2. PubMed PMID: 25411640; PubMed Central PMCID: PMC4236430.
11. Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. PubMed PMID: 27092830.
12. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. The New England journal of medicine. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. PubMed PMID: 28891408.
13. Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. Journal of the American Academy of Dermatology. 2015 May;72(5):780-5 e3. doi: 10.1016/j.jaad.2015.01.009. PubMed PMID: 25748297.
14. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1):175-83. doi: 10.1158/1078-0432.CCR-13-3316. PubMed PMID: 25564571.
15. Zager JS, Gastman, B. R., Messina, J., Sondak, V. K., Ferris, L., Cook, R. W., Middlebrook, B. M., Johnson, C., Maetzold, D., Monzon, F. A., Wayne, J. D, Gerami, P. . Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(15_suppl):9581.
16. Hsueh EC, DeBloom JR, Lee J, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol. 2017 Aug 29;10(1):152. doi: 10.1186/s13045-017-0520-1. PubMed PMID: 28851416; PubMed Central PMCID: PMCPMC5576286.
17. Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016 May 23;32(9):1599-1604. doi: 10.1080/03007995.2016.1192997. PubMed PMID: 27210115.
18. Farberg AS, Glazer AM, White R, et al. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions. J Drugs Dermatol. 2017 May 01;16(5):428-431. PubMed PMID: 28628677.
19. Schuitevoerder D, Heath M, Cook RW, et al. Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging. J Drugs Dermatol. 2018;In Press.
20. Coit DG, Thompson JA, Algazi A, et al. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2016 Apr;14(4):450-73. PubMed PMID: 27059193.
21. Del Vecchio M, Ascierto PA, Mandala M, et al. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future oncology. 2015;11(9):1355-62. doi: 10.2217/fon.15.55. PubMed PMID: 25952781.
22. Kaufman H AT, Nemunaitis JJ, Chesne, JA, Delman KA, Spitler LE, Collichio FA, Ross MI, Zhang Y, Shilkrut M, Andtbacka RHI. Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). Journal of Clinical Oncology. 2015;33(15_suppl):9074.
23. Steinman J, Ariyan C, Rafferty B, et al. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. Journal of surgical oncology. 2014 Apr;109(5):405-9. doi: 10.1002/jso.23519. PubMed PMID: 24318953.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.